Myo-inositol modulates insulin and luteinizing hormone secretion in normal weight patients with polycystic ovary syndrome

J Obstet Gynaecol Res. 2014 May;40(5):1353-60. doi: 10.1111/jog.12319. Epub 2014 Mar 9.


Aim: To investigate hormonal dynamics in a group of non-obese polycystic ovary syndrome (PCOS) patients under myo-inositol (MYO) administration.

Methods: Hormonal profiles, insulin response to oral glucose tolerance test (OGTT) and luteinizing hormone (LH) response to gonadotropin-releasing hormone (GnRH) stimulation test before and after the administration of a preparation of MYO (3 g p.o. daily) mixed with lactoferrin and bromelin, in a group (n = 24) of normal weight PCOS patients.

Results: After the treatment interval, body mass index (BMI) did not change while LH, LH/follicle-stimulating hormone, 17-hydroxy-progesterone and androstenedione decreased significantly. Insulin response to OGTT was significantly reduced after the treatment interval (P < 0.05) as well as GnRH-induced LH response (P < 0.05). High-sensitivity C-reactive protein decreased significantly after the treatment interval.

Conclusion: MYO administration positively modulates insulin sensitivity in non-obese PCOS patients without compensatory hyperinsulinemia, improving hormonal parameters. The presence of bromelin in the formulation modulated the pro-inflammatory state that characterizes PCOS, independently of BMI.

Keywords: C-reactive protein; hyperinsulinism; insulin resistance; myo-inositol; polycystic ovary syndrome.

MeSH terms

  • Body Weight
  • C-Reactive Protein / analysis
  • Female
  • Glucose Tolerance Test
  • Gonadotropin-Releasing Hormone / pharmacology
  • Humans
  • Inositol / pharmacology*
  • Insulin / metabolism*
  • Insulin Secretion
  • Luteinizing Hormone / metabolism*
  • Polycystic Ovary Syndrome / drug therapy
  • Polycystic Ovary Syndrome / metabolism*


  • Insulin
  • Gonadotropin-Releasing Hormone
  • Inositol
  • Luteinizing Hormone
  • C-Reactive Protein